# European Patent Office

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/european-patent-office
Canonical HTML page: https://getbiobrief.com/entity/european-patent-office

## Timeline

- **2026-Q3**: Bioequivalence Studies — Projected commencement of studies required for regional regulatory filings.
- **2026-03-17**: Strategic Agreement Signed — BioNxt announces a commercialization deal for Cladribine ODF in the Eurasian region.
- **2026-03-17**: Patent Grants Confirmed — Patents for the ODF formulation are officially granted in Europe and Eurasia.

## Recent coverage (2 stories)

### HYFT Stock Jumps 2.3% on Patent to Own the Data Layer for AI Drug Discovery
2026-07-07 04:16:55 · Sentiment: Positive · Impact: 7/10 · Sources: 3

MindWalk’s European patent application for a high-dimensional biological data architecture could give it a proprietary platform for AI-native pharma R&D. The filing underscores a strategic pivot from model development to data infrastructure.
Full story: https://getbiobrief.com/story/mindwalk-biotech-data-layer-patent

### BioNxt Secures Eurasian Commercialization Deal for Cladribine ODF
2026-03-17 08:34:27 · Sentiment: Positive · Impact: 6/10 · Sources: 2

BioNxt Solutions has entered a strategic partnership to commercialize its Cladribine Oral Dissolvable Film (ODF) across Eurasia, following successful patent approvals in both Europe and the Eurasian region. This move positions the company to capture market share in the Multiple Sclerosis (MS) treatment space with a novel, patient-friendly delivery mechanism.
Full story: https://getbiobrief.com/story/bionxt-cladribine-odf-eurasian-commercialization

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.